靶向 KRAS 突变型结直肠癌：联合治疗策略的进展
Targeting -Mutant Colorectal Cancer: Progress in Combination Strategies.
作者信息
Sundar Raghav, Hong David S, Kopetz Scott, Yap Timothy A
机构信息
Royal Marsden Hospital, London, UK.
National University Health System, Singapore.
出版信息
Cancer Discov. 2017 Jun;7(6):558-560. doi: 10.1158/2159-8290.CD-17-0087.
Abstract
BRAF mutations in colorectal cancer portend a poor prognosis, with first-line treatment often involving triplet or quadruplet chemotherapy, and single-agent targeted therapy with BRAF inhibitors failing to demonstrate clinical activity. Blockade of multiple critical nodes along the MAPK and other pathways may be necessary to improve response rates and survival. Cancer Discov; 7(6); 558-60. 2017 AACR..
摘要
结直肠癌中的BRAF突变预示着预后不良，一线治疗通常采用三联或四联化疗，而使用BRAF抑制剂的单药靶向治疗未能显示出临床活性。可能需要阻断丝裂原活化蛋白激酶（MAPK）及其他途径上的多个关键节点，以提高缓解率和生存率。《癌症发现》；7（6）；558 - 60。2017年美国癌症研究协会。
相似文献
1
Targeting -Mutant Colorectal Cancer: Progress in Combination Strategies.
Cancer Discov. 2017 Jun;7(6):558-560. doi: 10.1158/2159-8290.CD-17-0087.
2
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Cancer Res. 2012 Feb 1;72(3):779-89. doi: 10.1158/0008-5472.CAN-11-2941. Epub 2011 Dec 16.
3
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.
Cancer Discov. 2016 Dec;6(12):1352-1365. doi: 10.1158/2159-8290.CD-16-0050. Epub 2016 Oct 11.
4
Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer.
Clin Colorectal Cancer. 2014 Sep;13(3):164-71. doi: 10.1016/j.clcc.2014.06.001. Epub 2014 Jun 23.
5
SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR V600E-mutant mCRC.
Future Oncol. 2024 Apr;20(11):653-663. doi: 10.2217/fon-2022-1249. Epub 2023 Oct 10.
6
LSD1 inhibition attenuates targeted therapy-induced lineage plasticity in BRAF mutant colorectal cancer.
Mol Cancer. 2025 Apr 23;24(1):122. doi: 10.1186/s12943-025-02311-z.
7
Systemic treatments for metastatic cutaneous melanoma.
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
8
BRAF-Directed Therapy in Metastatic Colorectal Cancer.
Cancer J. 2016 May-Jun;22(3):175-8. doi: 10.1097/PPO.0000000000000189.
9
A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.
Cancer. 2024 May 15;130(10):1784-1796. doi: 10.1002/cncr.35200. Epub 2024 Jan 23.
10
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
Clin Cancer Res. 2013 Feb 1;19(3):657-67. doi: 10.1158/1078-0432.CCR-11-1446. Epub 2012 Dec 18.
引用本文的文献
1
A Contrast-Enhanced CT-Based Deep Learning System for Preoperative Prediction of Colorectal Cancer Staging and RAS Mutation.
Cancers (Basel). 2023 Sep 10;15(18):4497. doi: 10.3390/cancers15184497.
2
Computed tomography-based radiomics nomogram for the pre-operative prediction of BRAF mutation and clinical outcomes in patients with colorectal cancer: a double-center study.
Br J Radiol. 2023 Aug;96(1148):20230019. doi: 10.1259/bjr.20230019. Epub 2023 May 17.
3
The application of radiomics in predicting gene mutations in cancer.
Eur Radiol. 2022 Jun;32(6):4014-4024. doi: 10.1007/s00330-021-08520-6. Epub 2022 Jan 20.
4
Spatial profiling of gastric cancer patient-matched primary and locoregional metastases reveals principles of tumour dissemination.
Gut. 2021 Oct;70(10):1823-1832. doi: 10.1136/gutjnl-2020-320805. Epub 2020 Nov 23.
5
BRAF drives dedifferentiation in small intestinal and colonic organoids and cooperates with mutant p53 and Apc loss in transformation.
Oncogene. 2020 Sep;39(38):6053-6070. doi: 10.1038/s41388-020-01414-9. Epub 2020 Aug 13.
6
Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer.
Cancer Manag Res. 2018 Aug 1;10:2289-2301. doi: 10.2147/CMAR.S170105. eCollection 2018.
7
A System-wide Approach to Monitor Responses to Synergistic BRAF and EGFR Inhibition in Colorectal Cancer Cells.
Mol Cell Proteomics. 2018 Oct;17(10):1892-1908. doi: 10.1074/mcp.RA117.000486. Epub 2018 Jul 3.
8
Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies.
Nat Commun. 2018 Jun 12;9(1):2287. doi: 10.1038/s41467-018-04506-z.
9
Promising New Agents for Colorectal Cancer.
Curr Treat Options Oncol. 2018 May 11;19(6):29. doi: 10.1007/s11864-018-0543-z.
10
Novel putative drivers revealed by targeted exome sequencing of advanced solid tumors.
PLoS One. 2018 Mar 23;13(3):e0194790. doi: 10.1371/journal.pone.0194790. eCollection 2018.
本文引用的文献
1
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).
J Clin Oncol. 2021 Feb 1;39(4):285-294. doi: 10.1200/JCO.20.01994. Epub 2020 Dec 23.
2
A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic -Mutant Colorectal Cancer.
Cancer Discov. 2017 Jun;7(6):610-619. doi: 10.1158/2159-8290.CD-16-0795. Epub 2017 Mar 31.
3
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.
Cancer Discov. 2016 Dec;6(12):1352-1365. doi: 10.1158/2159-8290.CD-16-0050. Epub 2016 Oct 11.
4
Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.
Cancer Res. 2016 Aug 1;76(15):4504-15. doi: 10.1158/0008-5472.CAN-16-0396. Epub 2016 Jun 16.
5
Are Doses and Schedules of Small-Molecule Targeted Anticancer Drugs Recommended by Phase I Studies Realistic?
Clin Cancer Res. 2016 May 1;22(9):2127-32. doi: 10.1158/1078-0432.CCR-15-1855. Epub 2015 Nov 18.
6
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.
J Clin Oncol. 2015 Dec 1;33(34):4032-8. doi: 10.1200/JCO.2015.63.2497. Epub 2015 Oct 12.
7
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.
J Clin Oncol. 2015 Dec 1;33(34):4023-31. doi: 10.1200/JCO.2015.63.2471. Epub 2015 Sep 21.
8
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
N Engl J Med. 2015 Aug 20;373(8):726-36. doi: 10.1056/NEJMoa1502309.
9
Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.
Clin Cancer Res. 2015 Mar 15;21(6):1313-20. doi: 10.1158/1078-0432.CCR-14-2779. Epub 2015 Jan 14.
10
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
Clin Cancer Res. 2013 Feb 1;19(3):657-67. doi: 10.1158/1078-0432.CCR-11-1446. Epub 2012 Dec 18.
Zotero 插件